openPR Logo
Press release

Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth

09-05-2017 09:56 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic

Global Hepatitis E Diagnostic Tests Market: Snapshot

The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene, making it imperative for the diagnosis of hepatitis E. These factors have spurred the demand for hepatitis E diagnostic tests, especially among young adults in the age of 15 to 40 years. The growing awareness of the related symptoms of the disease has propelled the growth of the market in various regions.

View Full Report:

The global hepatitis E diagnostic tests market is anticipated to rise at a CAGR of 3.80% from 2016 to 2024. The market was valued at US$43.7 mn in 2015 and expected to reach US$60.4 mn by the end of the forecast period.

The global hepatitis E diagnostic tests market is extremely competitive with the leading players adopting a competitive pricing strategy of various diagnostic tests, including the kits used for the primary ELISA HEV IgM tests.

Request to view Sample Report:

Hepatitis E Hyper-endemicity in Asian Economies to Ensure Dominance of Asia Pacific Region

On the basis of geography, the global market is segmented into Europe, Asia Pacific, Latin America, North America, and the Middle East and Africa. Of these, Asia Pacific is the leading regional market. The impressive growth of the market is attributed to hepatitis E assuming endemic proportions in various Asian countries, especially resource-poor regions, such as Nepal, Vietnam, Pakistan, Bangladesh, Burma, Kazakhstan, Thailand, and Bhutan. The regional market is poised to attain a share of over 48% by the end of 2024.

Besides, the Middle East and Africa is expected to witness a steady and substantial demand for the hepatitis E diagnostic tests. The growth in the regional market is driven by increasing prevalence of hepatitis E in countries such as Kenya, Uganda, Nigeria, and Morocco attributable to poor hygienic conditions, limited access to safe drinking water, and lack of sanitation. The soaring number of people suffering from Hepatitis E, especially the prevalence of the disease across pregnant women, has made it a public health concern in the region. Consequently, the governments of various countries of Africa are making evidence-based control policies, including the modes of transmission. Timely treatment calls for extensive tests for people who are more prone to infections, especially those using contaminated piped water. This has spurred the demand for Hepatitis E diagnostic tests fuelling the regional market.

Request to download and view full ToC -

North America and Europe markets are expected to witness only incremental growth over the forecast period.

RT-PCR diagnostic Test Gaining Wide Adoption

Among the different types of diagnostic tests for hepatitis E, the primary tests are ELISA HEV IgM test kits, ELISA HEV IgG test kits, and RT-PCR test kits. The market has witnessed an extensive demand for ELISA HEV IgM test kits. Owing to growing seroprevalence of hepatitis E across the globe, market analysts expect the demand for ELISA HEV IgM diagnostic test kits to soar significantly over the forecast period. The demand for RT-PCR test kits is expected to closely follow that of ELISA HEV IgM test kits in the coming years. The use of RT-PCR diagnostic test among clinicians is propelled by the rapid generation of results and the high sensitivities and specificities of the molecular assay. On the other hand, the ELISA HEV IgG test kits segment is expected to register a modest growth along the forecast period.

Companies vying for a significant share in the global market for hepatitis E diagnostic tests include Beijing Wantai Biological Pharmacy, Primerdesign Ltd., Mikrogen GmBH, MP Biomedicals LLC, Fast-track diagnostics Ltd., Fortress Diagnostics Ltd., F. Hoffmann-La Roche Ltd., Biokit S.A., and Altana Diagnostics GmbH.

Global Hepatitis E Diagnostic Tests Market Report is available @ US$ 5795:

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth here

News-ID: 698415 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases

More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Hepatitis C Drug Market: Global Hepatitis C Drug Share Will Reach $27.63 billion …
Zion Market Research has published a new report titled “Hepatitis C Drug Market for (Hospitals, Private Labs, Physician Offices, Public Health Labs and Blood Banks) by Application – Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021” According to the report, global demand for hepatitis C drug market was valued at USD 11.81 billion in 2015, is expected to reach USD 27.63 billion in 2021 and is anticipated to